FLT3

Assoc. Prof. Alexander E. Perl | 2017 ASCO Annual Meeting | Phase III study of gilteritinib versus salvage chemotherapy in R/R FLT3 mutation-positive AML

L:

2017 ASCO Annual Meeting - 2-6 June, Chicago